Franchini Massimo
Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Str. Lago Paiolo 10, Mantova, 46100, Italy.
Methods Mol Biol. 2017;1646:43-56. doi: 10.1007/978-1-4939-7196-1_3.
Increasing evidence supports the existence of a close relationship between immunotransfusion, hemostasis, and thrombosis. The best example of such linkage is given by the influence of the ABO blood group antigens on von Willebrand factor (VWF) plasma levels and activity. It is well known, for instance, that individuals with non-O blood type (i.e., A, B, and AB) have higher VWF and factor VIII plasma levels than O blood type subjects and are consequently exposed to an increased thrombotic risk. There is also a close relationship between immunotransfusion, hemostasis, and thrombosis testing. The first part of this narrative review is dedicated to the issue of the relationship between immunotransfusion, hemostasis, and thrombosis, while the second part is focused on the relationship between immunotransfusion and hemostasis and thrombosis testing, as well as the effects on hemostasis of the transfusion of blood components (i.e., red blood cells, platelet concentrates, and fresh frozen plasma) and plasma-derived products.
越来越多的证据支持免疫输血、止血和血栓形成之间存在密切关系。这种联系的最佳例子是ABO血型抗原对血管性血友病因子（VWF）血浆水平和活性的影响。例如，众所周知，非O血型（即A、B和AB型）的个体比O血型的个体具有更高的VWF和因子VIII血浆水平，因此面临更高的血栓形成风险。免疫输血、止血和血栓形成检测之间也存在密切关系。本叙述性综述的第一部分致力于免疫输血、止血和血栓形成之间的关系问题，而第二部分则侧重于免疫输血与止血和血栓形成检测之间的关系，以及血液成分（即红细胞、浓缩血小板和新鲜冰冻血浆）和血浆衍生产品输血对止血的影响。
